WCLC 2016: Epitinib in EGFRm+ NSCLC Patients with Brain Metastasis

A Phase Ib study of Epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NSCLC patients with brain metastasis

Qing Zhou¹, Bin Gan¹, Qunying Hong², Mengzhao Wang³, XiaoQing Liu⁴, Liwei Yuan⁵, Ye Hua⁵, Hongcan Ren⁵, Weiguo Su⁵, Yi-Long Wu¹

¹Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou/China, ²Zhongshan Hospital, Shanghai Fudan University, Shanghai/China, ³Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing/China, ⁴307 Hospital, PLA, Beijing/China, ⁵Hutchison MediPharma Ltd, Shanghai/China